Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476115 | 1.00 | CNR2 (0.88) | CNR2 | |
| SCHEMBL476174 | 1.00 | CNR2 (0.88) | CNR2 | |
| SCHEMBL476113 | 1.00 | CNR2 (0.88) | CNR2 | |
| SCHEMBL475229 | 0.94 | CNR2 (1.00) | CNR2 | |
| SCHEMBL475231 | 0.94 | CNR2 (1.00) | CNR2 | |
| SCHEMBL2815462 | 0.88 | CNR2 (0.85) | CNR2 | |
| SCHEMBL476007 | 0.88 | CNR2 (0.85) | CNR2 | |
| SCHEMBL476009 | 0.88 | CNR2 (0.85) | CNR2 | |
| SCHEMBL2815466 | 0.88 | CNR2 (0.85) | CNR2 | |
| SCHEMBL475952 | 0.86 | CNR2 (0.80) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411370-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-2411370-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | claimed |
| US-20100249087-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | claimed |
| WO-2010111573-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | claimed |
| EP-2411370-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8288428-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2411370-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249087-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010111573-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249087-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.